PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

Clinical trial NCT06196580 · COMPLETED

Trial details

NCT number: NCT06196580
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Gout and Hyperuricemia

Start date: 2024-01-04
Primary completion: 2024-02-16
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.